Product Description: Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Paola Galozzi, et al. Progress in Biological Therapies for Adult-Onset Still's Disease. Biologics. 2022 Apr 21;16:21-34. /[2]Brennan S, et al. Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study[J]. medRxiv, 2024: 2024.07. 01.24309808./[3]Bindoli S, et al. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. Drugs. 2024 Mar;84(3):257-274./[4]Macovei LA, et al. Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment. Int J Mol Sci. 2022 Oct 24;23(21):12810./[5]Galozzi P, et al. Progress in Biological Therapies for Adult-Onset Still's Disease. Biologics. 2022 Apr 21;16:21-34.
CAS Number: 2492472-82-7
Molecular Weight: N/A
Compound Purity: 98.41
Research Area: Cancer; Inflammation/Immunology; Cardiovascular Disease
Solubility: 10 mM in DMSO
Target: Interleukin Related
English
Deutsch
